Filana Therapeutics, Inc. (FLNA.MX)
Mexico · MXN · Healthcare · Biotechnology
MX$11.30 (-29.02%) as of
Key statistics
- EPS (TTM)
- -15.66
- Dividend yield
- 0.00%
- 52-week range
- 11.30 – 84.00
- Beta
- -0.66
- Profit margin
- 0.00%
- Volume
- 16.00
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Austin, TX, United States
- Employees
- 17
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.